A 10-Cent Heart Drug Just Cut Heart Failure Hospitalizations by 25%

If you’ve been managing heart failure for a while, there’s a good chance your cardiologist has never once mentioned digoxin. It fell out of favor decades ago, pushed aside by newer, pricier drugs. But new research out of the Netherlands — published in two of the most respected medical journals in the world — is making a serious case that this old-school medication deserves a second look. This isn’t a case of nostalgia or anecdote. It’s rigorous, large-scale data, and it’s already got cardiologists talking about adding a fifth option to standard heart failure treatment.

The Penny Heart Drug’s New Proof

Heart failure affects millions of people, and it wears people down. The heart can’t pump blood the way it should, so fluid builds up, breathing gets harder, and patients keep ending up back in the hospital. Right now, standard treatment relies on four medications working together, sometimes nicknamed the “Fantastic Four.” Cardiologists at the University Medical Center Groningen just made a strong case for adding a fifth drug to that lineup: digoxin, a medicine that’s been around for centuries.

Researchers ran three separate studies, presented together in 2026 and published in Nature Medicine and JAMA. The main one, called DECISION, followed 1,001 heart failure patients for about three years, giving half of them a low dose of digoxin along with their usual medications. On its own, that trial’s results weren’t strong enough to call a clear win. But when researchers combined DECISION with two earlier studies — nearly 9,000 patients total — the results became clear: digoxin lowered the chance of a heart failure flare-up bad enough to need hospital care by 25%. It also cut the combined risk of dying from heart problems or having one of those flare-ups by 15%.

One more finding worth knowing: patients who’d been taking digoxin and then stopped ran into more trouble over the next six weeks than patients who’d never taken it.

Two takeaways matter most here. Digoxin didn’t reduce the risk of death itself — deaths were about the same either way. And it looked safe: side effects were no worse than a placebo. For a drug that costs less than ten cents a day, next to several euros a day for many newer heart failure drugs, that’s a compelling deal.

Why Dose Makes All the Difference With This Drug

Digoxin isn’t new. It’s actually the oldest heart medicine still in use, first derived from the foxglove plant. Doctors have prescribed it for generations, but the way it’s used today looks nothing like it did decades ago.

Back then, doctors gave patients higher doses. The thinking was simple: digoxin makes heart muscle cells squeeze harder, so a bigger dose should mean a stronger pump. Some patients did seem to benefit at first. But over time, evidence showed high doses caused more harm than good, including higher death rates. Here’s the thing: a struggling heart doesn’t need to work harder. It needs less strain, not more.

Low doses work through a different, gentler mechanism. Instead of forcing the heart to contract more, they dial down some of the body’s stress responses. When the heart weakens, it releases more adrenaline and other stress hormones to compensate. That compensation is part of what wears the heart out over time. Low-dose digoxin blunts that stress response, easing the load without pushing the heart to overwork itself.

That difference is why the target dose in this trial was so specific. Doctors aimed for a blood level between 0.5 and 0.9 nanograms per milliliter — well below what was once considered standard. Earlier research had hinted this lower range worked better, but no large study had confirmed it directly until now.

As safer, more effective heart failure drugs rolled out over the past 25 to 30 years, digoxin use steadily dropped. Today, only about 15% of heart failure patients take it. This new data gives cardiologists a real reason to reconsider that decline.

What This Means for People Living With Heart Failure

These findings matter most for a specific group: people with heart failure and a reduced or mildly reduced ejection fraction, meaning the heart’s pumping chamber isn’t squeezing out as much blood as it should with each beat. That’s most patients living with this diagnosis today, and it’s exactly who these trials studied — patients already using the standard four-drug combination.

One especially reassuring piece of information involves women. Older data on digoxin created lingering concern that the drug might carry extra risk specifically for women. Researchers built this trial with that history in mind, and the results were clear: low-dose digoxin was just as safe in women as in men, with no difference in outcomes between the two groups. The same held true for patients with atrial fibrillation, a common companion condition to heart failure, and for patients in normal heart rhythm.

Across the board, side effects tracked closely with placebo. There was no increase in digestive symptoms, a known concern with digoxin at higher doses in the past, and no increase in the need for pacemakers or other devices. Serious adverse events happened at nearly identical rates in both groups.

None of this means digoxin should replace any of your current heart failure medications. This drug was tested as an addition on top of standard therapy, not a substitute for it. What it does mean is that researchers now have a stronger, more current case to bring to the medical groups that write treatment guidelines — and that case could open the door for far more patients to get this option in the years ahead.

Cheap Drugs Rarely Get This Kind of Research

Here’s an uncomfortable truth about drug research: cheap medications rarely get expensive trials built around them. Digoxin has been off-patent for decades, so no company stands to profit from proving it works. That’s part of why it took this long to get a properly designed, large-scale trial testing low-dose digoxin against a placebo. Studies like this typically depend on public funding rather than pharmaceutical companies footing the bill, and public funding is harder to secure.

In this case, the Dutch Heart Foundation covered the cost, contributing three million euros through a program built specifically to study how existing, inexpensive medications are used. Without that kind of support, a drug this affordable and this well-established might never have gotten the rigorous testing that newer, patented drugs go through as a matter of course.

The price gap here is real. Digoxin runs less than ten cents a day. Many newer heart failure medications cost several euros a day, and that adds up fast for patients paying out of pocket or health systems covering large populations. A fifth treatment option this cheap, if guidelines catch up to the evidence, could ease that financial pressure without asking patients to give up any of the drugs already proven to help them.

That’s likely the next step: getting this data in front of the panels that write heart failure treatment guidelines. If they act on it, low-dose digoxin could move from a rarely used, mostly forgotten option back into routine care for the right patients. Sometimes the best next treatment isn’t a new drug. It’s a second look at an old one.

My Personal RX to Make Heart Medications Work Better

Digoxin or not, most of what protects your heart day to day isn’t a prescription — it’s what you do between doctor visits. I tell my heart failure patients the same thing every time: your medications do their job better when your habits aren’t working against them. Here’s what I actually recommend.

1. Walk most days. Twenty to thirty minutes of easy walking conditions your heart muscle without overtaxing it.
2. Cut back on sodium. Excess salt makes your heart work harder to manage fluid balance — read labels, not just the salt shaker.
3. Get your magnesium. It plays a direct role in heart rhythm and muscle function. Leafy greens and nuts are a good start; I also point patients toward Magnesium Essentials when levels need a boost food alone won’t cover.
4. Work in omega-3s. Fatty fish twice a week supports heart rhythm and lowers inflammation. If fish isn’t realistic for you, a supplement like Omega-3 Fish Oil covers the same ground.
5. Protect your sleep. Short or broken sleep raises blood pressure and adds strain your heart doesn’t need.
6. Know your numbers — weight included. Blood pressure, cholesterol, blood sugar, and body weight should all be checked regularly, not just when something feels off. Extra weight raises your heart’s workload directly, so if that’s part of your plan, the Weight Loss Bundle (built around MetaBurn, which specifically targets blood pressure, blood sugar, and cholesterol balance) supports the same markers you’re already tracking.
7. Manage stress deliberately. Chronic stress hormones tax the heart the same way they do in heart failure — find something that actually lowers yours, whether that’s exercise, therapy, or a few minutes of quiet daily.
8. Never stop a heart medication on your own. The digoxin research above is a good reminder: stopping abruptly can cause real problems. Always talk to your doctor first.
9. Limit alcohol. It’s harder on the heart than most people assume.
10. Stay connected. Social isolation is consistently linked to worse heart outcomes — relationships are part of your treatment plan too.

Sources:

1. D. J. van Veldhuisen, M. Rienstra, A. Mosterd, M. Alings, A. A. Voors, K. Damman, A. D. I. van Asselt, M. L. Bouvy, J. Schaap, E. E. van der Wall, H. J. G. M. Crijns, D. J. Touw, P. A. M. Hoogslag, J. E. C. van de Swaluw, R. J. Schuurman, A. van der Sluis, O. Bondarenko, T. J. Römer, T. Oosterhof, G. L. Bartels, S. Koudstaal, P. A. Dijkmans, G. C. M. Linssen, I. Aksoy, H. G. R. Dorman, A. Schut, M. E. W. Hemels, R. G. Tieleman, D. J. A. Lok, I. C. D. Westendorp, M. A. T. Vijver, G. H. D. Voordes, A. H. de Vos, E. L. Maas-Soer, D. Postmus, G. Lunter, J. G. P. Tijssen, P. van der Meer. Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial. Nature Medicine, 2026; 32 (7): 2647 DOI: 10.1038/s41591-026-04406-6
2. Kevin Damman, Dirk J. van Veldhuisen, Johann Bauersachs, Michiel Rienstra, Arend Mosterd, Adriaan A. Voors, Geert H. D. Voordes, Udo Bavendiek, Peter van der Meer. Efficacy and Safety of Digitalis Glycosides in Heart Failure. JAMA, 2026; 335 (23): 2029 DOI: 10.1001/jama.2026.7886